2-Year Nonrecurrence Linked With Improved Long-Term Survival With Haplo-SCT
Researchers sought to determine whether there could be a link between haplo-SCT and survival in patients with hematologic malignancies who remain disease free for 2 years.
Diagnosis & Disease Information
Camidanlumab Tesirine Appears Safe, Effective in Relapsed/Refractory Classical Hodgkin Lymphoma
Researchers sought to determine whether camidanlumab tesirine would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Orca-T Improves Outcomes After Myeloablative Conditioning for Hematologic Malignancies
Researchers sought to determine whether Orca-T would improve outcomes for GVHD- and relapse-free survival after myeloablative conditioning.
Disparities in Multiple Myeloma Diagnosis and Outcomes Identified in Hispanic Patients
Researchers sought to determine whether there were disparities in diagnosis and outcomes in Hispanic patients with multiple myeloma.
Safety Profile of Isatuximab Confirmed in Real-World Study of Patients With Multiple Myeloma
Researchers sought to determine the real-world safety profile of isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory MM.
Patients With Diffuse Large B-Cell Lymphoma May Benefit From Shared Decision Making Schemes
Researchers sought to determine whether educational tools would help caregivers and physicians to better account for the lived experiences of some patients with DLBCL.
DOACs May Be a Viable Alternative to LMWH in Venous Thromboembolism
Researcher sought to determine whether DOACs would be an alternative to low molecular weight heparin in patients with lymphoma or plasma cell dyscrasia with VTE.
Though Improved, Outcomes Remain Poor for Patients With MDS Who Progress on HMA Therapy
Researchers sought to determine outcomes in patients with MDS whose disease progressed during treatment with hypomethylating agents.
Azacitidine May Improve Outcomes in a Subset of Patients With AML
Researchers sought to determine the safety and efficacy of oral azacitidine vs placebo among patients with AML.
Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL
Researchers sought to determine whether zanubrutinib would have superior clinical outcomes to ibrutinib in patients with CLL/SLL.
- Loading...
Loading...
Next post in SOHO 2022
Loading... 
Loading...